Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SMMT logo SMMT
Upturn stock ratingUpturn stock rating
SMMT logo

Summit Therapeutics PLC (SMMT)

Upturn stock ratingUpturn stock rating
$26.45
Last Close (24-hour delay)
Profit since last BUY5.8%
upturn advisory
Consider higher Upturn Star rating
BUY since 25 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SMMT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $35.21

1 Year Target Price $35.21

Analysts Price Target For last 52 week
$35.21 Target price
52w Low $11.29
Current$26.45
52w High $36.91

Analysis of Past Performance

Type Stock
Historic Profit 102.64%
Avg. Invested days 41
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 19.65B USD
Price to earnings Ratio -
1Y Target Price 35.21
Price to earnings Ratio -
1Y Target Price 35.21
Volume (30-day avg) 10
Beta -1.06
52 Weeks Range 11.29 - 36.91
Updated Date 08/15/2025
52 Weeks Range 11.29 - 36.91
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.01

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.09
Actual -0.12

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -142.53%
Return on Equity (TTM) -328.3%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 19355975474
Price to Sales(TTM) 753.9
Enterprise Value 19355975474
Price to Sales(TTM) 753.9
Enterprise Value to Revenue 6425.28
Enterprise Value to EBITDA -5.32
Shares Outstanding 742846976
Shares Floating 116084649
Shares Outstanding 742846976
Shares Floating 116084649
Percent Insiders 84.3
Percent Institutions 13.04

ai summary icon Upturn AI SWOT

Summit Therapeutics PLC

stock logo

Company Overview

overview logo History and Background

Summit Therapeutics PLC is a biopharmaceutical company focused on developing and commercializing medicines for unmet medical needs. Founded in 2003, it has undergone several strategic shifts, including focusing on novel therapies for Duchenne muscular dystrophy and later concentrating on oncology.

business area logo Core Business Areas

  • Oncology: Focused on developing novel therapies for cancer. Their lead product candidates are aimed at solid tumors.

leadership logo Leadership and Structure

The company is led by a board of directors and an executive management team. Specific details are available in their investor relations section, often including the CEO, CFO, and Chief Scientific Officer.

Top Products and Market Share

overview logo Key Offerings

  • Ivonacap: Ivonacap is being studied for treatment of tumors. Clinical trials are ongoing. Market share data is not available as it is not yet approved. Major competitors include companies developing treatments for similar tumor types. Competition depends on the specific tumor being targeted.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and research-intensive. It involves developing, manufacturing, and marketing medications. Key trends include personalized medicine, gene therapy, and increasing regulatory scrutiny.

Positioning

Summit Therapeutics is positioned as a research and development company focusing on novel cancer therapies. Their competitive advantage depends on the success of their clinical trials and the uniqueness of their drug candidates.

Total Addressable Market (TAM)

The TAM for cancer therapies is very large, in the hundreds of billions of dollars, due to the prevalence of the disease and the high cost of treatment. Summit Therapeutics is positioning to capture a portion of this TAM through successful commercialization of their products.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • Dependence on clinical trial success
  • Limited commercialization experience
  • High cash burn rate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline through acquisitions
  • Positive clinical trial results leading to regulatory approval

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • PFE
  • AZN

Competitive Landscape

Summit Therapeutics faces intense competition from larger, more established pharmaceutical companies with greater resources. Its success depends on its ability to develop and commercialize innovative therapies.

Growth Trajectory and Initiatives

Historical Growth: Summit Therapeutics' growth has been primarily driven by its research and development activities. Historical revenue and earnings have been volatile due to the nature of the biopharmaceutical industry.

Future Projections: Future growth depends on the success of its drug candidates in clinical trials and subsequent regulatory approvals. Analyst estimates are not available in this response.

Recent Initiatives: Focus on clinical trials for Ivonacap.

Summary

Summit Therapeutics is a biopharmaceutical company focused on oncology. Its strength lies in its drug candidates. Its weakness lies in its dependence on positive clinical trial results. Investors should monitor clinical trial data and regulatory decisions.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Market share data is approximate and based on available information.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Summit Therapeutics PLC

Exchange NASDAQ
Headquaters Miami, FL, United States
IPO Launch date 2015-03-05
Co-CEO & Executive Chairman Mr. Robert W. Duggan
Sector Healthcare
Industry Biotechnology
Full time employees 159
Full time employees 159

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.